10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer’s disease: A prospective study in eight cohorts

      research-article
      a , b , c , d , e , a , c , f , c , f , b , c , f , c , f , g , h ,   h , i , j , k , l , m , g , n , o , p , e , e , q , r , e , s , t , u , v , g , o , p , p , n , n , w , x , w , x , y , z , aa , bb , c , cc , h , dd , e , ee , b , c , ff , g
      Alzheimer's & dementia : the journal of the Alzheimer's Association
      Dementia, Alzheimer’s disease, Metabolomics, Biomarkers, Amino acids

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Metabolite, lipid, and lipoprotein lipid profiling can provide novel insights into mechanisms underlying incident dementia and Alzheimer’s disease.

          Methods

          We studied eight prospective cohorts with 22,623 participants profiled by nuclear magnetic resonance or mass spectrometry metabolomics. Four cohorts were used for discovery with replication undertaken in the other four to avoid false positives. For metabolites that survived replication, combined association results are presented.

          Results

          Over 246,698 person-years, 995 and 745 cases of incident dementia and Alzheimer’s disease were detected, respectively. Three branched-chain amino acids (isoleucine, leucine, and valine), creatinine and two very low density lipoprotein (VLDL)-specific lipoprotein lipid subclasses were associated with lower dementia risk. One high density lipoprotein (HDL; the concentration of cholesterol esters relative to total lipids in large HDL) and one VLDL (total cholesterol to total lipids ratio in very large VLDL) lipoprotein lipid subclass was associated with increased dementia risk. Branched-chain amino acids were also associated with decreased Alzheimer’s disease risk and the concentration of cholesterol esters relative to total lipids in large HDL with increased Alzheimer’s disease risk.

          Discussion

          Further studies can clarify whether these molecules play a causal role in dementia pathogenesis or are merely markers of early pathology.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Metabolic network failures in Alzheimer's disease: A biochemical road map.

          The Alzheimer's Disease Research Summits of 2012 and 2015 incorporated experts from academia, industry, and nonprofit organizations to develop new research directions to transform our understanding of Alzheimer's disease (AD) and propel the development of critically needed therapies. In response to their recommendations, big data at multiple levels are being generated and integrated to study network failures in disease. We used metabolomics as a global biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            2-Aminoadipic acid is a biomarker for diabetes risk.

            Improvements in metabolite-profiling techniques are providing increased breadth of coverage of the human metabolome and may highlight biomarkers and pathways in common diseases such as diabetes. Using a metabolomics platform that analyzes intermediary organic acids, purines, pyrimidines, and other compounds, we performed a nested case-control study of 188 individuals who developed diabetes and 188 propensity-matched controls from 2,422 normoglycemic participants followed for 12 years in the Framingham Heart Study. The metabolite 2-aminoadipic acid (2-AAA) was most strongly associated with the risk of developing diabetes. Individuals with 2-AAA concentrations in the top quartile had greater than a 4-fold risk of developing diabetes. Levels of 2-AAA were not well correlated with other metabolite biomarkers of diabetes, such as branched chain amino acids and aromatic amino acids, suggesting they report on a distinct pathophysiological pathway. In experimental studies, administration of 2-AAA lowered fasting plasma glucose levels in mice fed both standard chow and high-fat diets. Further, 2-AAA treatment enhanced insulin secretion from a pancreatic β cell line as well as murine and human islets. These data highlight a metabolite not previously associated with diabetes risk that is increased up to 12 years before the onset of overt disease. Our findings suggest that 2-AAA is a marker of diabetes risk and a potential modulator of glucose homeostasis in humans.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study.

              To investigate whether dementia incidence has changed over the last 2 decades. We compared dementia incidence in 2 independent subcohorts of persons aged 60-90 years from the Rotterdam Study, a population-based cohort study. The first subcohort started in 1990 (n = 5,727), the second in 2000 (n = 1,769). Participants were dementia-free at baseline and followed for at maximum 5 years. We calculated age-adjusted dementia incidence rates for the 2 subcohorts in total, in 10-year age strata, and for men and women separately. We also compared mortality rates, differences in prevalence of vascular risk factors, and medication use. Finally, we compared brain volumes and the extent of cerebral small vessel disease in participants who underwent brain imaging 5 years after the baseline examinations. In the 1990 subcohort (25,696 person-years), 286 persons developed dementia, and in the 2000 subcohort (8,384 person-years), 49 persons. Age-adjusted dementia incidence rates were consistently, yet nonsignificantly, lower in the 2000 subcohort in all strata, reaching borderline significance in the overall analysis (incidence rate ratio 0.75, 95% confidence interval [CI] 0.56-1.02). Mortality rates were also lower in the 2000 subcohort (rate ratio 0.63, 95% CI 0.52-0.77). The prevalence of hypertension and obesity significantly increased between 1990 and 2000. This was paralleled by a strong increase in use of antithrombotics and lipid-lowering drugs. Participants in 2005-2006 had larger total brain volumes (p < 0.001) and less cerebral small vessel disease (although nonsignificant in men) than participants in 1995-1996. Although the differences in dementia incidence were nonsignificant, our study suggests that dementia incidence has decreased between 1990 and 2005.
                Bookmark

                Author and article information

                Journal
                101231978
                33173
                Alzheimers Dement
                Alzheimers Dement
                Alzheimer's & dementia : the journal of the Alzheimer's Association
                1552-5260
                1552-5279
                29 June 2018
                06 March 2018
                June 2018
                08 August 2018
                : 14
                : 6
                : 723-733
                Affiliations
                [a ]Department of Cardiology, Tays Heart Hospital, Tampere University Hospital and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
                [b ]Department of Neurology, Boston University School of Medicine, Boston, MA, USA
                [c ]The Framingham Heart Study, Framingham, MA, USA
                [d ]Lille University, Inserm, Lille University Hospital, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, Labex Distalz, Lille, France
                [e ]Department of Epidemiology, ErasmusMC, Rotterdam, The Netherlands
                [f ]Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
                [g ]Department of Health, National Institute for Health and Welfare, Helsinki, Finland
                [h ]Department of Epidemiology and Public Health, University College London, London, UK
                [i ]INSERM, U1018, Centre for Research in Epidemiology and Population Health, France
                [j ]Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
                [k ]Broad Institute of MIT and Harvard, Cambridge, MA, USA
                [l ]Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
                [m ]Vanderbilt Heart and Vascular Institute, Vanderbilt University School of Medicine, Nashville, TN, USA
                [n ]Nightingale Health Ltd, Helsinki, Finland
                [o ]Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland
                [p ]Estonian Genome Center, University of Tartu, Tartu, Estonia
                [q ]Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
                [r ]Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
                [s ]Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland
                [t ]Department of Clinical Chemistry, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
                [u ]Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland
                [v ]Department of Clinical Physiology, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
                [w ]Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland
                [x ]NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland
                [y ]Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK
                [z ]Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
                [aa ]Systems Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
                [bb ]Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia
                [cc ]Department of Medicine, Sections of Preventive Medicine and Cardiology, Boston University School of Medicine, Boston, MA, USA
                [dd ]Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland
                [ee ]Leiden Academic Center for Drug Reseach (LACDR), Leiden University, Leiden, The Netherlands
                [ff ]Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA
                Author notes
                [* ]Corresponding author. Tel.: +001 210 450 8426; Fax: +001 210 450 2250
                [** ]Corresponding author. Tel.: +358 29 524 8620; Fax: +358 29 524 8338. suseshad@ 123456bu.edu (S.S.), veikko.salomaa@ 123456thl.fi (V.S.)
                [†]

                These authors contributed equally as first authors.

                [‡]

                These authors contributed equally as senior authors.

                Article
                NIHMS975867
                10.1016/j.jalz.2018.01.003
                6082422
                29519576
                02f9cd19-1313-43b7-ae24-432000218e87

                This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Article

                dementia,alzheimer’s disease,metabolomics,biomarkers,amino acids

                Comments

                Comment on this article